Sedana Medical AB (SE:SEDANA)
:SEDANA
SEDANA Stock Chart & Stats
kr10.72
-kr0.18(-1.05%)
At close: 4:00 PM EST
kr10.72
-kr0.18(-1.05%)
Day’s Range― - ―
52-Week Rangekr6.65 - kr18.32
Previous CloseN/A
Volume45.94K
Average Volume (3M)247.68K
Market Cap
kr876.15M
Enterprise Valuekr789.87M
Total Cash (Recent Filing)kr90.98M
Total Debt (Recent Filing)kr4.70M
Price to Earnings (P/E)―
Beta0.92
Next Earnings
Apr 23, 2026EPS Estimate
-0.03Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding99,336,960
10 Day Avg. Volume186,290
30 Day Avg. Volume247,675
Financial Highlights & Ratios
PEG Ratio-0.04
Price to Book (P/B)1.13
Price to Sales (P/S)5.10
P/FCF Ratio-13.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.23
Revenue Forecast (FY)kr217.50M
Bulls Say, Bears Say
Bulls Say
Recurring Consumable RevenueSedana’s core device business generates repeatable per‑patient consumable sales tied to ventilated ICU patients. This unit-based recurring model creates predictable revenue streams as patient volumes scale, supporting durable top-line growth and long-term commercial visibility.
Strong Revenue Growth & Gross MarginsSustained double‑digit revenue expansion and high gross margins indicate strong product economics and market traction. High product gross margins give room to invest in commercialization and R&D while scaling, increasing the odds of eventual operating leverage if revenue growth persists.
Low Leverage, Strong Balance SheetA very low‑debt capital structure and substantial equity/assets provide financial flexibility to fund commercialization, regulatory work and short‑term cash burn without urgent refinancing. This reduces solvency risk and supports continued investment during growth phases.
Bears Say
Negative Cash GenerationPersistent negative operating and free cash flow means the business consumes cash to grow. Unless cash generation turns positive, the company will rely on external financing to fund operations, increasing dilution risk and potentially constraining long‑term strategic flexibility.
Ongoing LossesDespite revenue growth, the company has not converted scale into profitability; a materially larger net loss in 2025 suggests operating costs or investments outpaced revenue gains. Continued losses raise questions on path to sustainable margins and shareholder returns.
Dependence On Adoption & ApprovalsCommercial success hinges on hospitals adopting inhaled sedation, securing reimbursement, and gaining regulatory clearances across markets. These structural adoption and regulatory hurdles can delay scale, prolong cash burn, and make revenue growth contingent on external healthcare system dynamics.
Sedana Medical AB News
SEDANA FAQ
What was Sedana Medical AB’s price range in the past 12 months?
Sedana Medical AB lowest stock price was kr6.65 and its highest was kr18.32 in the past 12 months.
What is Sedana Medical AB’s market cap?
Sedana Medical AB’s market cap is kr876.15M.
When is Sedana Medical AB’s upcoming earnings report date?
Sedana Medical AB’s upcoming earnings report date is Apr 23, 2026 which is in 16 days.
How were Sedana Medical AB’s earnings last quarter?
Sedana Medical AB released its earnings results on Feb 12, 2026. The company reported -kr0.1 earnings per share for the quarter, missing the consensus estimate of -kr0.069 by -kr0.031.
Is Sedana Medical AB overvalued?
According to Wall Street analysts Sedana Medical AB’s price is currently Overvalued.
Does Sedana Medical AB pay dividends?
Sedana Medical AB does not currently pay dividends.
What is Sedana Medical AB’s EPS estimate?
Sedana Medical AB’s EPS estimate is -0.03.
How many shares outstanding does Sedana Medical AB have?
Sedana Medical AB has 99,336,960 shares outstanding.
What happened to Sedana Medical AB’s price movement after its last earnings report?
Sedana Medical AB reported an EPS of -kr0.1 in its last earnings report, missing expectations of -kr0.069. Following the earnings report the stock price went up 11.715%.
Which hedge fund is a major shareholder of Sedana Medical AB?
Currently, no hedge funds are holding shares in SE:SEDANA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Sedana Medical AB
Sedana Medical AB (publ), a medical technology company, develops, markets, and sells medical devices in Sweden and internationally. The company offers Sedaconda ACD-L and Sedaconda ACD-, which are disposable medical devices that enables the administration of volatile anesthetics; Sedaconda Syringe, a 50/60ml syringe; Sedaconda ACD starter kit; FlurAbsorb and FlurAbsorb-S, which are active carbon filters to capture waste anaesthetic gases from the exhaust of the ventilator; FlurAbsorb accessory kit comprising accessories to connect the exhaust of the ventilator and the gas monitor to the FlurAbsorb/FlurAbsorb-S; and FlurAbsorb mount to hold the filter during scavenging of anesthetic gas. It also provides AMG-06 Gas Monitor for continuous non-invasive sidestream monitoring of CO2 and anaesthetics concentration in inspired and expired gases; Sedaconda Filling Adapter, a single-use device for safe and easy extraction of isoflurane from a Sedaconda bottle to a Sedaconda Syringe; and various accessories comprising DRYLINE II Water Traps, WaterLock 2 water trap, Nafion Dryer Tubing, and Respiratory Gas Monitoring Line. Sedana Medical AB (publ) was founded in 1999 and is headquartered in Danderyd, Sweden.
Technical Analysis
Options Prices
Currently, No data available
---